S
Syndesi Therapeutics
Developer of a series of novel, procognitive SV2A modulators
About Syndesi Therapeutics
Syndesi Therapeutics was a clinical-stage biotechnology company headquartered in Louvain-la-Neuve, Belgium, dedicated to developing novel treatments for cognitive impairment. Established in 2017 as a corporate spinoff from the biopharmaceutical major UCB, Syndesi focused on a unique class of small molecules that modulate the synaptic vesicle protein 2A (SV2A). Its lead asset, SDI-118, was designed to enhance synaptic efficiency directly at the nerve terminal, addressing the underlying synaptic dysfunction common in neurodegenerative and neuropsychiatric conditions such as Alzheimer’s disease and major depression.
The company’s rapid growth trajectory culminated in a landmark acquisition by AbbVie in March 2022. Valued at up to $1 billion, the deal included a $130 million upfront payment with potential milestone payments reaching $870 million, validating the high strategic value of Syndesi’s "first-in-class" mechanism. Prior to this exit, Syndesi had secured a €17 million Series A backed by a robust syndicate including Novo Holdings, Fountain Healthcare Partners, and Johnson & Johnson Innovation (JJDC), positioning it as a standout example of successful corporate venture building in the European life sciences sector.
Syndesi Therapeutics serves as a prime case study of effective technology transfer between a large pharmaceutical incumbent (UCB) and an agile startup structure. By rapidly advancing the SDI-118 program through early clinical validation (Phase 1b), the team successfully attracted a global heavy hitter in neuroscience, delivering a significant return to its investors while accelerating the potential delivery of new cognitive therapies to patients.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 28.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, Sustainable Development Goals, Biotech and Pharma, Longevity, proteomics, DT and LS, science-based
- Technology
- Hardware
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2022 | $130M | $130M | AbbVie | ↗ |
| SERIES AEquity / VC | Sep 2020 | $6.6M | $26M | Fountain Healthcare Partners · V-Bio Ventures · UCB Ventures · Novo Seeds | — |
Growth signals
Latest recorded traffic for Syndesi Therapeutics is 140 monthly website visits, down 98.2% over the last three months. Syndesi Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Syndesi Therapeutics in the Wavre ecosystem
The Syndesi Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Novo Ventures
Fountain Healthcare Partners
Wallonie Entreprendre
Johnson & Johnson Innovation
Vives Partners
Novo Seeds
V-Bio Ventures
UCB Ventures
Series B and later1 investor entered at this stage
UCB
Other known investors4 additional known investors
AbbVie
Bioqube Ventures
Novo Holdings
WE Venture
Source: Dealroom Talent Intelligence.
Global footprint
See Syndesi Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









